MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

Macular Degeneration Clinical Trial

Official title:

Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00094120
• Other study ID #: MSI-1256F-208
• Status: Terminated
• Phase: Phase 2
• First received: October 11, 2004
• Last updated: January 8, 2008
• Start date: October 2004
• Est. completion date: February 2007

Study information

• Verified date: November 2007
• Source: Genaera Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Age-Related Macular Degeneration (AMD) is a degenerative disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula.

Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine when administered with verteporfin therapy in patients with "wet" AMD.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 60
• Est. completion date: February 2007
• Est. primary completion date: February 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of "wet" age-related macular degeneration

Exclusion Criteria:

• Prior treatment for "wet" age-related macular degeneration

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Macular Degeneration

Intervention

Drug:
• MSI-1256F (Squalamine Lactate)

Locations

Country	Name	City	State
United States	Genaera Corporation	Plymouth Meeting	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Genaera Corporation

Country where clinical trial is conducted

United States,